RankAlpha logo
Back to Rankings

BDTX

Black Diamond TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The readout is the main bull hook: the company says Phase 2 silevertinib data were positive and supportive of pivotal development, while the balance sheet appears sufficient into 2H 2028. The limited target summary in the packet shows a $9.29 median, implying meaningful upside if the clinical signal is replicated and the market believes the development path is de-risked.
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +4.2.
What can break
Cash runway extends into 2H 2028, but financing risk is not eliminated beyond that point.
Momentum
77
Value
54
Sentiment
100
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $3.50 · Bull $7.25 · Bear $1.10
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.29
Why
Momentum77 · Δ7d -16.3
Value54 · Δ7d +0.1
Sentiment100 · Δ7d +4.2
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
77
34% active weight
Current posture
7d trendImproving
Δ7d
-16.3
Δ21d
-16.3
Value
54
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
-15.2
Sentiment
100
33% active weight
Current posture
7d trendSoftening
Δ7d
+4.2
Δ21d
+4.2
Why this grade

Composite grade A. Momentum 77.0 / Value 53.5 / Sentiment 100.0

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$129.5M
Beta
3.37
Shares Out
56.97M
P/E (TTM)
7.1
P/S (TTM)
2.09
P/FCF (TTM)
6.86
Rev YoY
-
EPS YoY
+45.8%
Gross Margin
-
Op Margin
+16.9%
Net Debt
-$98.58M
Current Ratio
8.94
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology